HC
HCM.US HUTCHMED DRC
- Market cap
- USD 2.59B
- P/E
- 149.0x
- P/B
- 2.05x
- ROE
- 2.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is HCM.US undervalued?
Graham numberThe Graham number of HUTCHMED DRC cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HUTCHMED DRC fundamental analysis
No fundamental analysis for HUTCHMED DRC yet.
HUTCHMED DRC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HUTCHMED DRC
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), …
Full company profileHUTCHMED DRC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HUTCHMED DRC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 216M | 241M | 214M | 205M | 228M | 356M | 426M | 838M | 630M | 550M | 557M |
| Gross Profit | 59.8M | 65.4M | 70.2M | 44.7M | 39.5M | 327M | 115M | 454M | 283M | 213M | 94.7M |
| Operating Income | -46.7M | -53.4M | -92.6M | -153M | -199M | -357M | -719M | 18.4M | -43.7M | -54.7M | 1.74M |
| EBITDA | -43.4M | -49.5M | -82.1M | -135M | -193M | -147M | -351M | 26.6M | -31.4M | -41.4M | 15.9M |
| Net Income | 11.7M | -26.7M | -74.8M | -106M | -126M | -195M | -361M | 101M | 37.7M | 458M | 31.9M |
| EPS | 0.10 | -0.22 | -0.56 | -0.80 | -4.51 | -1.23 | -2.13 | 0.58 | 0.22 | 2.62 | 0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 342M | 598M | 532M | 465M | 724M | 1.37B | 1.03B | 1.28B | 1.27B | 1.75B | 1.74B |
| Total Liabilities | 138M | 113M | 120M | 152M | 205M | 333M | 393M | 536M | 502M | 502M | 461M |
| Shareholders' Equity | 184M | 462M | 389M | 288M | 484M | 987M | 610M | 731M | 760M | 1.24B | 1.26B |
| Cash & Short-term Investments | 104M | 358M | 301M | 217M | 435M | 1.01B | 631M | 886M | 836M | 1.37B | 1.38B |
| Total Debt | 57.2M | 32.6M | 27.8M | 33.4M | 38.9M | 39.0M | 27.0M | 86.1M | 89.8M | 97.9M | 94.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.57M | -8.94M | -32.8M | -80.9M | -62.1M | -204M | -269M | 219M | 497K | -64.7M | 24.4M |
| Capital Expenditure | 4.33M | 5.02M | 6.36M | 8.57M | 19.6M | 16.8M | 36.7M | 32.6M | 17.9M | 24.1M | 11.3M |
| Free Cash Flow | -13.9M | -14.0M | -39.2M | -89.5M | -81.6M | -221M | -305M | 187M | -17.4M | -88.8M | 13.2M |
| Ratios | |||||||||||
| ROE | 6.3% | -5.8% | -19.2% | -36.8% | -26.0% | -19.7% | -59.1% | 13.8% | 5.0% | 37.0% | 2.5% |
| ROA | 3.4% | -4.5% | -14.1% | -22.8% | -17.4% | -14.2% | -35.1% | 7.9% | 3.0% | 26.1% | 1.8% |
| Net Profit Margin | 5.4% | -11.1% | -34.9% | -51.7% | -55.2% | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% | 5.7% |
| Debt to Equity | 0.31x | 0.07x | 0.07x | 0.12x | 0.08x | 0.04x | 0.04x | 0.12x | 0.12x | 0.08x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HUTCHMED DRC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 123M | 0.71 | 122.5% |
| 2022 | USD 87.4M | 0.52 | - |
| 2021 | USD 99.7M | 0.63 | - |
| 2020 | USD 35.0K | 0.00 | - |
| 2019 | USD 28.1M | 0.21 | - |
| 2018 | USD 24.9M | 0.19 | - |
| 2017 | USD 55.6M | 0.45 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on May 30, 2019.
Who owns HUTCHMED DRC
- Insiders 0.06%
- Institutions 2.54%
- Public & others 97.40%
- Shares outstanding 174M
- Free float 106M
Top funds holding HCM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| M&G Global Emerging Markets GBP I Acc | 182K | 0.11% | -2.62% | Jul 2026 |
| Steward Values Enhanced International I | 106K | 0.06% | +12.30% | Sep 2026 |
| BSO Bio Santé C | 100K | 0.06% | 0.00% | Oct 2026 |
| State Street® SPDR® Ptf Dev Wld exUS ETF | 72.3K | 0.04% | 0.00% | Oct 2026 |
| M&G (Lux) Glb Em Mkts C USD Acc | 55.4K | 0.03% | 0.00% | Jul 2026 |
| Stt Strt SPDR MSCI Emg Mkts SmCapETF | 45.0K | 0.03% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 16.4K | 0.01% | -22.03% | Aug 2026 |
| Dimensional World Equity GBP Acc | 6.49K | 0.00% | -0.22% | Sep 2026 |
| DFA International Core Equity Class F | 6.43K | 0.00% | 0.00% | Aug 2026 |
| Dimensional Emerging Markets Cr Eq 2 ETF | 5.57K | 0.00% | 0.00% | Oct 2026 |
| Acadian Select Em Mkts Equity A GBP Acc | 2.65K | 0.00% | 0.00% | Oct 2026 |
| Acadian Emerg Mkts Eq II A USD Acc | 2.15K | 0.00% | 0.00% | Oct 2026 |
| Dimensional World ex US Core Eq 2 ETF | 2.11K | 0.00% | 0.00% | Oct 2026 |
| DFA Emerging Markets Core Equity 2 I | 1.68K | 0.00% | 0.00% | Sep 2026 |
| Dimensional World Eq LC ESG Sc EUR A | 1.54K | 0.00% | -0.13% | Sep 2026 |
| Dimensional World Allc 60/40 GBP Acc | 1.51K | 0.00% | -34.95% | Sep 2026 |
| Dimensional Emerging Mrkts Sstby Cr 1ETF | 1.31K | 0.00% | 0.00% | Oct 2026 |
| Dimensional EM Cor Eq LC ESG Sc USD A | 876.00 | 0.00% | -0.34% | Sep 2026 |
| Eurizon Equity Emerging Mkts LTE Z Acc | 27.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding HCM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Schroder Investment Management Group | 1.48M | 0.85% | 0.00% | Jun 2026 |
| Allianz Asset Management AG | 675K | 0.39% | -19.46% | Jun 2026 |
| State Street Corp | 314K | 0.18% | +2.88% | Jun 2026 |
| AIA Group Ltd | 291K | 0.17% | 0.00% | Jun 2026 |
| M&G PLC | 243K | 0.14% | -4.96% | Jun 2026 |
| Amundi | 204K | 0.12% | -12.00% | Jun 2026 |
| Jane Street Group LLC | 194K | 0.11% | +154.17% | Jun 2026 |
| Renaissance Technologies Corp | 116K | 0.07% | -10.83% | Sep 2026 |
| BNP Paribas Arbitrage, SA | 104K | 0.06% | -1.95% | Jun 2026 |
| XY Capital Ltd | 104K | 0.06% | +115.17% | Jun 2026 |
| Crossmark Global Holdings, Inc. | 84.9K | 0.05% | -0.06% | Jun 2026 |
| Two Sigma Investments LLC | 63.2K | 0.04% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 61.9K | 0.04% | -4.96% | Sep 2026 |
| UBS Group AG | 44.2K | 0.03% | -1.28% | Jun 2026 |
| JustInvest LLC | 42.6K | 0.02% | +108.56% | Jun 2026 |
| Citadel Advisors Llc | 38.1K | 0.02% | +24.73% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 35.6K | 0.02% | -8.52% | Sep 2026 |
| Vident Advisory, LLC | 26.6K | 0.02% | +49.97% | Jun 2026 |
| Millennium Management LLC | 26.4K | 0.02% | -5.69% | Jun 2026 |
| StoneX Group Inc | 18.3K | 0.01% | 0.00% | Jun 2026 |
HUTCHMED DRC company profile
- Company name
- HUTCHMED DRC
- Ticker
- HCM.US
- Exchange
- USA Stocks
- Listed since
- Mar 17, 2016
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,790
- Fiscal year end
- December
- Address
- Cheung Kong Center, Hong Kong, Hong Kong
- Phone
- 852 2121 8200
- Website
- hutch-med.com
About HUTCHMED DRC
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
HUTCHMED DRC management
10- Mr. Chig Fung Cheng BEc, CAActing CEO, CFO & Executive Director · born 1967
- Dr. Wei-Guo Su B.Sc., Ph.D.CEO, Chief Scientific Officer & Executive Director (Leave of Absence) · born 1959
- Ms. Yiling CuiExecutive VP & Head of Operations
- Dr. Xinhui Hu Ph.D.Executive Vice President & Chief Technical Officer · born 1973
- Mr. Charles George Rupert NixonGroup General Counsel · born 1970
- Mr. Kin Hung Lee M.B.A.Senior Vice President of Corporate Management & Communications · born 1977
- Ms. Selina ZhangSenior Vice President of Global Human Resources
- Dr. Qingmei Wang Ph.D.Executive Vice President of Business Development & Strategic Alliances · born 1963
- Dr. Thomas FuSenior Vice President of Global Quality
- Mr. George YuanExecutive VP & Head of Commercial of China